SCHEMBL6791707

SCHEMBL6791707

Cc1cccc2c(Cl)c3ccccc3nc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.61
MAOB P27338 1/20 0.61
KDM1A O60341 1/20 0.48
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
HCRTR1 O43613 1/20 0.46
RAB9A P51151 1/20 0.46
CYP1A2 P05177 2/20 0.44
PARP1 P09874 2/20 0.44
TNKS O95271 2/20 0.44
TNKS2 Q9H2K2 2/20 0.44
GPR3 P46089 1/20 0.42
ELANE P08246 1/20 0.42
ALDH1A1 P00352 2/20 0.42
CYP2A6 P11509 1/20 0.42
BACE1 P56817 1/20 0.42
RAD52 P43351 1/20 0.41
TP53 P04637 1/20 0.41
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27977387 0.81 KDM1A (0.50) MAOAKDM1AMEN1KMT2ANPC1
SCHEMBL11060901 0.79 CYP1A2 (0.66) MAOAKDM1AMEN1KMT2ANPC1
SCHEMBL30182735 0.79 CYP1A2 (0.66) MAOAKDM1AMEN1KMT2ANPC1
SCHEMBL28054584 0.78 MAOA (0.61) MAOAMAOBCYP1A2PARP1GPR3
SCHEMBL17060429 0.78 CYP1A2 (0.50) KDM1AMEN1KMT2ANPC1HCRTR1
SCHEMBL12886828 0.78 KDM1A (0.48) MAOAKDM1AMEN1KMT2ANPC1
SCHEMBL1186255 0.78 KDM1A (0.48) MAOAKDM1AMEN1KMT2ANPC1
SCHEMBL15131691 0.78 MAOA (0.73) MAOAMAOBMEN1KMT2ANPC1
SCHEMBL7122711 0.77 NQO2 (0.59) MAOAMAOBKDM1AMEN1KMT2A
SCHEMBL27889436 0.77 MAOA (1.00) MAOAMAOBKDM1AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111057004-B N-o-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof 宁波大学 2023-10-31 CN disclosed
CN-111057004-A N-ortho-substituted phenyl benzamide-4-methylaminoacridine compound and preparation method and application thereof 宁波大学 2020-04-24 CN disclosed
EP-1940965-B1 NOVEL FLUORESCENT DYES AND USES THEREOF ALMAC SCIENCES SCOTLAND LTD (GB) 2014-03-26 EP disclosed
US-20080176889-A1 9-anilinoacridine alkylating agents ACADEMIA SINICA (TW) 2008-07-24 US disclosed
US-6821983-B2 INHIBITORS OF TOPOISOMERASE II CAN EXHIBIT ANTITUMOR ACTIVITY ACADEMIA SINICA (TW) 2004-11-23 US disclosed
US-20040198765-A1 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS ACADEMIA SINICA (TW) 2004-10-07 US disclosed
US-4795826-A CHEMICAL INTERMEDIATES FOR BACTERICIDES AND ANTITUMOR AGENTS ATWELL GRAHAM J (NZ) 1989-01-03 US disclosed
EP-0095355-B1 SUBSTITUTED O-PHENYLENEDIAMINE COMPOUNDS WARNER-LAMBERT COMPANY (US) 1987-05-27 EP disclosed
EP-0073155-B1 COMPOUNDS HAVING ANTITUMOUR ACTIVITY WARNER-LAMBERT COMPANY (US) 1986-10-29 EP disclosed
US-4603125-A Substituted o-phenylenediamine acridine compounds having antitumor activity DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) 1986-07-29 US disclosed
US-4537729-A ANTITUMOR AGENTS DEVELOPMENT OF FINANCE CORPORATION OF NEW ZEALAND (NZ) 1985-08-27 US disclosed
US-4479000-A ANTITUMOR AGENTS DEVELOPMENT FINANCE CORPORATION OF NEW ZEALAND (NZ) 1984-10-23 US disclosed
EP-0095355-A1 Substituted o-phenylenediamine compounds WARNER-LAMBERT COMPANY (US) 1983-11-30 EP disclosed
EP-0073155-A2 Compounds having antitumour activity WARNER-LAMBERT COMPANY (US) 1983-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176889-A1 9-anilinoacridine alkylating agents BCL9, MCL1, BCL9L MAOA 4191/4885MAOB 4361/4885KDM1A 1168/4885
US-20040198765-A1 5-(9-ACRIDINYLAMINO)-TOLUIDINE COMPOUNDS DPP9, NANP, NAT1 MAOA 820/4885MAOB 1338/4885KDM1A 3382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.